Heart Failure - Cytokinetics CY 9021

Heart Failure – Cytokinetics CY 9021

Participating in a clinical trial with Profound means making a real difference in the lives of others facing similar health challenges.

This is a Phase 2 dose-finding study in adult participants with symptomatic HFpEF.

Inclusion Criteria:

Males and females ≥ 40 years and ≤ 85 years of age at screening.
Diagnosed with HF with NYHA functional class II or III.
Screening echocardiography with LVEF ≥ 60%.
Screening NT-proBNP ≥ 300 pg/mL for participants in sinus rhythm and ≥ 900 pg/mL for participants with comorbid atrial fibrillation or flutter.
Body mass index < 40 kg/m2.
Participants on beta-blockers, angiotensin-converting enzyme (ACE)/angiotensin II receptor blocker (ARB) or angiotensin receptor/neprilysin inhibitor (ARNI), must be on stable doses for more than 30 days prior to screening.
Participants on a glucagon-like peptide-1 (GLP-1) agonist must be on a stable dose for more than 24 weeks prior to screening with no anticipated plans to change dose during this study.
Other criteria may apply

Complete the form and our team will reach out soon to help determine your eligibility.

View Study on ClinicalTrials.gov

Trial Interest Form

I am a...

First Name(Required)

Last Name(Required)

Location(Required)

Phone(Required)

Email(Required)

Gender

Conditions

Race

Contact Preference

How did you hear about us?

Other (Please specify)

This field is hidden when viewing the form

Trial (Origination Page)

This field is hidden when viewing the form

UTM Source

This field is hidden when viewing the form

UTM Medium

This field is hidden when viewing the form

UTM Campaign

Name(Required)

First Last

Email(Required)

Enter Email Confirm Email

Phone(Required)

Zip Code(Required)

What is the best way to contact you?(Required)

Comments(Required)

Please let us know what's on your mind. Have a question for us? Ask away.

This field is hidden when viewing the form

Origination Page

Heart Failure – Cytokinetics CY 9021